Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2025-06-19 Proxy Solicitation & In…
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Solicitation of Proxy Reference Document) and is filed by HLB Life Science Co., Ltd. It provides detailed information regarding an upcoming Extraordinary General Meeting (EGM) to vote on a merger with HLB Co., Ltd. It includes the purpose of the meeting, voting procedures (electronic/written), merger details, and financial statements of the involved companies. This document is a formal proxy solicitation material sent to shareholders to request their votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-06-19 Korean
전환가액의조정 (제13회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from HLB Life Science regarding the adjustment of the conversion price (Refixing) for its 13th series of convertible bonds. This type of filing, which details changes to the capital structure and potential future share issuance due to price adjustments, falls under the category of capital and financing updates.
2025-05-29 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a merger (회사합병 결정) between HLB and HLB Life Science. It details the amendment (정정신고) of the merger schedule, share issuance numbers, and appraisal rights. This falls under M&A activity as it pertains to a corporate merger proposal and its subsequent updates.
2025-05-19 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal regulatory filing titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders) and specifically a '정정신고' (Correction Report) regarding the schedule of an Extraordinary General Meeting. It details the change in meeting date, location, and electronic voting procedures. Since this document is a formal notice of a shareholder meeting and its procedural details, it falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to participate in the upcoming meeting.
2025-05-19 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for HLB Life Science Co., Ltd. for the period ending March 31, 2025. It contains comprehensive financial and business information, including company overview, business segments, capital changes, and management discussion. It is a formal regulatory filing submitted to the Financial Supervisory Service (FSS) and Korea Exchange (KRX). According to the definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
기타시장안내 (에이치엘비생명과학 9WR 신주인수권 행사기간 만료 및 상장폐지 예고)
Delisting Announcement Classification · 100% confidence The document is a short announcement regarding the expiration of warrant exercise periods and the subsequent delisting of a specific financial instrument (9WR). It does not constitute a full report but rather a regulatory notice regarding market activity and listing status. Given the specific nature of the delisting and expiration notice, it falls under the RNS (Regulatory Filings) category as a general market announcement.
2025-04-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.